Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme Therapeutics (NASDAQ: HALO) announced the pricing of a $625 million offering of convertible senior notes due 2028, upsized from an initial $500 million. The notes will bear an interest rate of 1.00% and are convertible at a rate of 17.8517 shares per $1,000 principal amount, equating to an initial conversion price of $56.02. Proceeds of approximately $608.7 million will be used for capped call transactions, repurchasing existing convertible notes, and share repurchases, among other corporate purposes, set to close on August 18, 2022.
Halozyme Therapeutics plans a $500 million offering of convertible senior notes due 2028, subject to market conditions, with an option for an additional $75 million. The company intends to use proceeds for capped call transactions, repurchasing shares up to $200 million, and repaying a $250 million term loan due 2026. The offering could potentially influence the market price of Halozyme's common stock.
Halozyme Therapeutics (HALO) announced its second quarter financial results for 2022, reporting a revenue increase of 12% year-over-year to $152.4 million. GAAP diluted EPS was $0.16, while non-GAAP EPS reached $0.53. The company raised its full-year revenue guidance to $655 million to $685 million, driven by strong royalty growth of 86% to $85.3 million and the recent acquisition of Antares Pharma. However, projected operating income and GAAP net income guidance decreased significantly due to acquisition-related costs. Halozyme remains optimistic about future growth with multiple upcoming product launches.
Halozyme Therapeutics (NASDAQ: HALO) announced positive results from Roche's Phase III IMscin001 study, evaluating a subcutaneous formulation of Tecentriq® using ENHANZE® technology. The study demonstrated non-inferior pharmacokinetics of Tecentriq when delivered subcutaneously compared to intravenous infusion in patients with advanced non-small cell lung cancer. Treatment time was significantly reduced to 3-8 minutes versus 30-60 minutes for IV. Roche plans to submit data for global regulatory approval.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced it will release its second quarter 2022 financial results on August 9, 2022, after market close. A conference call will follow at 4:30 p.m. ET with dial-in numbers provided for both domestic and international callers. Halozyme is recognized for its ENHANZE® technology, enhancing drug delivery. With over 600,000 patients impacted, it has commercial products and partnerships with major pharmaceutical companies. For more details, visit www.halozyme.com.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that CEO Dr. Helen Torley will present at the Goldman Sachs 43rd Annual Global Healthcare Conference from June 14-16, 2022 in Rancho Palos Verdes, CA. Her presentation is scheduled for June 15, 2022, at 8:00 a.m. PT / 11:00 a.m. ET. The event will feature a fireside chat format and one-on-one meetings. A live audio webcast will be accessible via the Investor Relations section of Halozyme’s website and will be available for replay for 90 days.
Halozyme Therapeutics announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy, on June 7, 2022. TLANDO was approved by the FDA on March 28, 2022. This launch follows the introduction of XYOSTED in 2018, marking Halozyme's second product in this category. Executives emphasized that TLANDO provides a convenient dosing option requiring no titration, targeting the growing market of male hypogonadism, estimated to affect 30-50% of men with obesity or type 2 diabetes.
Halozyme Therapeutics has successfully completed its acquisition of Antares Pharma, finalizing the payment for shares tendered at $5.60 each. This strategic acquisition aims to enhance Halozyme's capabilities in biopharmaceutical development, particularly through its proprietary ENHANZE® technology, which aims to improve patient treatment experiences. Antares, now a wholly-owned subsidiary, will cease trading on NASDAQ following this merger. Financial advisors included BofA Securities and Wells Fargo, confirming the significant market interest in this consolidation.
Halozyme Therapeutics announced the expiration of the waiting period under the HSR Act for its acquisition of Antares Pharma. The tender offer commenced on April 26, 2022, at a price of $5.60 per share. The offer's completion is contingent upon the tendering of a majority of Antares shares and other customary conditions. The offer is set to expire on May 23, 2022, unless extended. This acquisition aims to enhance Halozyme's innovative therapy offerings, leveraging Antares' expertise in drug delivery systems.
Halozyme Therapeutics reported a strong first quarter of 2022, with revenue of $117.3 million, marking a 32% year-over-year increase. GAAP diluted earnings per share rose to $0.43 while non-GAAP diluted EPS reached $0.47. Record quarterly royalties hit $69.6 million, an 89% growth compared to the prior year. The company reiterated its full-year 2022 revenue guidance of $530 million to $560 million, forecasting 20-26% growth and a GAAP operating income of $350 million to $380 million.